Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
1.
Tuberculosis and Respiratory Diseases ; : 231-233, 2012.
Article in English | WPRIM | ID: wpr-148474

ABSTRACT

Tadalafil is a phosphodiesterase-5 inhibitor (PDE5I), which is widely used to treat erectile dysfunction. Although PDE5Is have excellent safety profiles, and most of the side effects are mild, rare serious adverse events have been reported in association with PDE5Is. Thrombosis is one of those events, and a few previous reports have suggested the association of PDE5Is with thrombosis. We report the case of a 61-year-old male who developed pulmonary embolism combined with pulmonary infarction directly after taking tadalafil. Both the patient and the physician suspected tadalafil as the culprit drug, as the patient was in an otherwise healthy condition. However, after extensive evaluation, we noticed that factor VIII levels were elevated. Prior reports suggesting the association between thrombosis and PDEIs either lack complete information on coagulation factors, or show inconsistencies in their results. Physicians should operate caution prior to accepting the diagnosis of adverse drug reaction.


Subject(s)
Humans , Male , Middle Aged , Blood Coagulation Factors , Carbolines , Cyclic Nucleotide Phosphodiesterases, Type 5 , Drug-Related Side Effects and Adverse Reactions , Erectile Dysfunction , Factor VIII , Phosphodiesterase 5 Inhibitors , Pulmonary Embolism , Pulmonary Infarction , Thrombosis , Tadalafil
SELECTION OF CITATIONS
SEARCH DETAIL